An update on molecular biology and drug resistance mechanisms of multiple myeloma
Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease...
Gespeichert in:
| Veröffentlicht in: | Critical reviews in oncology/hematology 2015-12, Vol.96 (3), p.413-424 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 424 |
|---|---|
| container_issue | 3 |
| container_start_page | 413 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 96 |
| creator | Mutlu, Pelin Kiraz, Yağmur Gündüz, Ufuk Baran, Yusuf |
| description | Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease to treat because of its marked resistance to chemotherapy. • This review deals with the molecular aspects of MM, drug resistance mechanisms during treatment and also possible new applications for overcoming drug resistance. |
| doi_str_mv | 10.1016/j.critrevonc.2015.07.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1747315140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1040842815300032</els_id><sourcerecordid>1747315140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c645t-82e455386caf3d1d1ce8d6dfa89521124fd10b8d87168ab356f186ff988ddc303</originalsourceid><addsrcrecordid>eNqNkUtr3TAQhU1paR7tXyhadmNHo5d1N4U0pA8IhNBkLXSlcapbWbqV7MD997W5aQtddTXDcM4M852mIUA7oKAudp0rYSr4lJPrGAXZ0b6jlL9oTkH3m5YKBS-XngraasH0SXNW645SKoTqXzcnTDEu5UacNneXicx7byckOZExR3RztIVsQ4758UBs8sSX-ZEUrKFONjkkI7rvNoU6VpIHMs5xCvu4jA8Y82jfNK8GGyu-fa7nzcOn6_urL-3N7eevV5c3rVNCTq1mKKTkWjk7cA8eHGqv_GD1RjIAJgYPdKu97kFpu-VSDaDVMGy09t5xys-b98e9-5J_zlgnM4bqMEabMM_VQC96DhLEKtVHqSu51oKD2Zcw2nIwQM0K1OzMX6BmBWpobxagi_Xd85V5O6L_Y_xNcBF8PApw-fUpYDHVBVww-VDQTcbn8D9XPvyzxMWQgrPxBx6w7vJc0sLSgKnMUPNtDXbNFSRfQuWM_wKuvaHO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1747315140</pqid></control><display><type>article</type><title>An update on molecular biology and drug resistance mechanisms of multiple myeloma</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Mutlu, Pelin ; Kiraz, Yağmur ; Gündüz, Ufuk ; Baran, Yusuf</creator><creatorcontrib>Mutlu, Pelin ; Kiraz, Yağmur ; Gündüz, Ufuk ; Baran, Yusuf</creatorcontrib><description>Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease to treat because of its marked resistance to chemotherapy. • This review deals with the molecular aspects of MM, drug resistance mechanisms during treatment and also possible new applications for overcoming drug resistance.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2015.07.003</identifier><identifier>PMID: 26235594</identifier><language>eng</language><publisher>Netherlands: Elsevier Ireland Ltd</publisher><subject>Antineoplastic Agents, Alkylating - pharmacology ; Drug Resistance ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Molecular aspects ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - genetics ; Multiple Myeloma - pathology ; Targeted drug delivery</subject><ispartof>Critical reviews in oncology/hematology, 2015-12, Vol.96 (3), p.413-424</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c645t-82e455386caf3d1d1ce8d6dfa89521124fd10b8d87168ab356f186ff988ddc303</citedby><cites>FETCH-LOGICAL-c645t-82e455386caf3d1d1ce8d6dfa89521124fd10b8d87168ab356f186ff988ddc303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.critrevonc.2015.07.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26235594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mutlu, Pelin</creatorcontrib><creatorcontrib>Kiraz, Yağmur</creatorcontrib><creatorcontrib>Gündüz, Ufuk</creatorcontrib><creatorcontrib>Baran, Yusuf</creatorcontrib><title>An update on molecular biology and drug resistance mechanisms of multiple myeloma</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease to treat because of its marked resistance to chemotherapy. • This review deals with the molecular aspects of MM, drug resistance mechanisms during treatment and also possible new applications for overcoming drug resistance.</description><subject>Antineoplastic Agents, Alkylating - pharmacology</subject><subject>Drug Resistance</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Molecular aspects</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - pathology</subject><subject>Targeted drug delivery</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtr3TAQhU1paR7tXyhadmNHo5d1N4U0pA8IhNBkLXSlcapbWbqV7MD997W5aQtddTXDcM4M852mIUA7oKAudp0rYSr4lJPrGAXZ0b6jlL9oTkH3m5YKBS-XngraasH0SXNW645SKoTqXzcnTDEu5UacNneXicx7byckOZExR3RztIVsQ4758UBs8sSX-ZEUrKFONjkkI7rvNoU6VpIHMs5xCvu4jA8Y82jfNK8GGyu-fa7nzcOn6_urL-3N7eevV5c3rVNCTq1mKKTkWjk7cA8eHGqv_GD1RjIAJgYPdKu97kFpu-VSDaDVMGy09t5xys-b98e9-5J_zlgnM4bqMEabMM_VQC96DhLEKtVHqSu51oKD2Zcw2nIwQM0K1OzMX6BmBWpobxagi_Xd85V5O6L_Y_xNcBF8PApw-fUpYDHVBVww-VDQTcbn8D9XPvyzxMWQgrPxBx6w7vJc0sLSgKnMUPNtDXbNFSRfQuWM_wKuvaHO</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Mutlu, Pelin</creator><creator>Kiraz, Yağmur</creator><creator>Gündüz, Ufuk</creator><creator>Baran, Yusuf</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>An update on molecular biology and drug resistance mechanisms of multiple myeloma</title><author>Mutlu, Pelin ; Kiraz, Yağmur ; Gündüz, Ufuk ; Baran, Yusuf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c645t-82e455386caf3d1d1ce8d6dfa89521124fd10b8d87168ab356f186ff988ddc303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antineoplastic Agents, Alkylating - pharmacology</topic><topic>Drug Resistance</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Molecular aspects</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - pathology</topic><topic>Targeted drug delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mutlu, Pelin</creatorcontrib><creatorcontrib>Kiraz, Yağmur</creatorcontrib><creatorcontrib>Gündüz, Ufuk</creatorcontrib><creatorcontrib>Baran, Yusuf</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mutlu, Pelin</au><au>Kiraz, Yağmur</au><au>Gündüz, Ufuk</au><au>Baran, Yusuf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An update on molecular biology and drug resistance mechanisms of multiple myeloma</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>96</volume><issue>3</issue><spage>413</spage><epage>424</epage><pages>413-424</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease to treat because of its marked resistance to chemotherapy. • This review deals with the molecular aspects of MM, drug resistance mechanisms during treatment and also possible new applications for overcoming drug resistance.</abstract><cop>Netherlands</cop><pub>Elsevier Ireland Ltd</pub><pmid>26235594</pmid><doi>10.1016/j.critrevonc.2015.07.003</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2015-12, Vol.96 (3), p.413-424 |
| issn | 1040-8428 1879-0461 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1747315140 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antineoplastic Agents, Alkylating - pharmacology Drug Resistance Hematology, Oncology and Palliative Medicine Humans Male Molecular aspects Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - pathology Targeted drug delivery |
| title | An update on molecular biology and drug resistance mechanisms of multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A31%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20update%20on%20molecular%20biology%20and%20drug%20resistance%20mechanisms%20of%20multiple%20myeloma&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Mutlu,%20Pelin&rft.date=2015-12-01&rft.volume=96&rft.issue=3&rft.spage=413&rft.epage=424&rft.pages=413-424&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2015.07.003&rft_dat=%3Cproquest_cross%3E1747315140%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1747315140&rft_id=info:pmid/26235594&rft_els_id=1_s2_0_S1040842815300032&rfr_iscdi=true |